CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CD123-targeted CAR-NK’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD123-targeted CAR-NK overview
The therapeutic is under development for the treatment of relapsed and refractory acute myeloid leukemia lymphoma and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The therapeutic candidate comprises of NK cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing CD123. It is administered through intravenous route.
For a complete picture of CD123-targeted CAR-NK’s drug-specific PTSR and LoA scores, buy the report here.